Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C W Ahn

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Transplantation|June 8, 2001
beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitusJ H Nam, J I Mun, S I Kim, et al.
Diabetes, Obesity & Metabolism|January 11, 2016
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialS Hong, C-Y Park, K A Han, et al.
Diabetes, Obesity & Metabolism|January 13, 2015
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, C-Y Park, Y M Cho, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumorsE M Newman, M Carroll, S A Akman, et al.
Acta Diabetologica|May 29, 2007
The clinical and immunogenetic characteristics of adult-onset type 1 diabetes mellitus in KoreaC S Kim, M K Song, J S Park, et al.
International Journal of Clinical Practice|January 23, 2013
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetesY-C Hwang, M Kang, C W Ahn, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Transplantation|June 8, 2001
beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitusJ H Nam, J I Mun, S I Kim, et al.
Diabetes, Obesity & Metabolism|January 11, 2016
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialS Hong, C-Y Park, K A Han, et al.
Diabetes, Obesity & Metabolism|January 13, 2015
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, C-Y Park, Y M Cho, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumorsE M Newman, M Carroll, S A Akman, et al.
Acta Diabetologica|May 29, 2007
The clinical and immunogenetic characteristics of adult-onset type 1 diabetes mellitus in KoreaC S Kim, M K Song, J S Park, et al.
International Journal of Clinical Practice|January 23, 2013
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetesY-C Hwang, M Kang, C W Ahn, et al.
Pageof 5